WASHINGTON — Nelson Mullins Riley & Scarborough LLP attorneys are representing Semper Paratus Acquisition Corporation, a special purpose acquisition company, in an enterprise-valued $1.2 billion merger agreement with Tevogen Bio Inc., an immunotherapy biotech company that focuses on T-cell therapy to treat COVID-19.

The Nelson Mullins deal team consists of Andy Tucker, Rebekah McCorvey, Sydney Hamer, Kathryn Johnson, Kaylen Loflin, Jeff Hendricks, Victoria Moreno Pabón, and Ana García Bodán. The newly merged companies will be listed on the New York Stock Exchange (NYSE) as TVGN.

The merger allows Tevogen Bio to continue pursuing clinical trials, expanding its research capabilities, and allowing them to seek new innovative methods for treatments, while also expediting the development process for products. The goal of the merger is for Tevogen Bio to be “a fully operational biotech company in less then 24 months,” according to the company press release. The merger is expected to be completed at the end of this year.

For the company press release, click here.

Established in 1897, Nelson Mullins is an Am Law 100 firm of more than 1,000 attorneys, policy advisors and professionals with 33 offices in 17 states and Washington, D.C. For more information, go to www.nelsonmullins.com.